文献速递前列腺癌

美国非转移性去势抵抗性前列腺癌患者雄激素受体抑制剂的真实世界分析:DEAR-EXT研究

Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2026-03-18

DEAR-EXT为美国泌尿外科实践中的回顾性病历审查,纳入2019年8月至2023年3月启动雄激素受体抑制剂(ARI)治疗的nmCRPC患者1375例。达罗他胺相比恩扎卢胺和阿帕他胺与更低的停药风险、更低的mCRPC进展风险及更长的MFS相关,且PSA缓解率更高、不良事件更少。

要点

  • 达罗他胺较恩扎卢胺和阿帕他胺显著降低停药风险(HR 0.73和0.69)。
  • 达罗他胺较其他ARI显著降低mCRPC进展风险并延长MFS。
  • 达罗他胺组24/36个月MFS率分别为72.3%/60.2%,高于其他ARI。

核心结论

  • 在真实世界nmCRPC患者中,达罗他胺相比恩扎卢胺和阿帕他胺与更低的停药率、更长的进展时间和更长的MFS相关。

研究设计与样本

  • DEAR-EXT为回顾性病历审查,纳入美国泌尿外科实践中2019年8月至2023年3月启动ARI治疗的nmCRPC患者,共1375例。
  • 患者接受达罗他胺(n=565,41%)、恩扎卢胺(n=609,44%)或阿帕他胺(n=201,15%)。
  • 主要分析采用校正Cox比例风险模型,并进行逆概率治疗加权和其他敏感性分析。

主要发现

  • 校正后停药风险达罗他胺 vs 恩扎卢胺 HR 0.73(95%CI 0.61-0.88),vs 阿帕他胺 HR 0.69(95%CI 0.54-0.89)。
  • 校正后mCRPC进展风险达罗他胺 vs 恩扎卢胺 HR 0.63(95%CI 0.50-0.80),vs 阿帕他胺 HR 0.72(95%CI 0.53-0.98)。
  • MFS达罗他胺 vs 恩扎卢胺 HR 0.65(95%CI 0.53-0.79),vs 阿帕他胺 HR 0.72(95%CI 0.55-0.93)。
  • 24/36个月估计MFS率:达罗他胺72.3%/60.2%,恩扎卢胺59.2%/48.3%,阿帕他胺63.9%/47.6%。
  • 真实世界中达罗他胺似乎与更高的PSA缓解、改善的生存和更少的不良事件相关,敏感性分析结果一致。

临床怎么用

  • 对于nmCRPC患者,达罗他胺可能作为优先考虑的ARI之一,以降低停药和进展风险并延长MFS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The real-world retrospective DEAR study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) demonstrated darolutamide was associated with lower risks of discontinuation and progression to metastatic castration-resistant disease vs enzalutamide and apalutamide. This analysis expands on DEAR, including additional patients and follow-up, comparing prostate-specific antigen (PSA) response, metastasis-free survival (MFS), and overall survival (OS). METHODS: DEAR-EXT was a chart review of electronic medical records from patients in US urology practices who initiated androgen receptor inhibitors (ARIs) for nmCRPC from August 2019-March 2023. Outcomes included time to initial drug discontinuation, time to metastatic castration-resistant prostate cancer (mCRPC), PSA response, MFS, OS, and safety. Adjusted Cox proportional hazards models were used for the primary analysis and inverse probability of treatment weighting and other sensitivity analyses were performed to evaluate the impact of potential selection bias and confounding factors. RESULTS: Patients (N = 1375) received darolutamide (n = 565, 41%), enzalutamide (n = 609, 44%), or apalutamide (n = 201, 15%). Baseline characteristics were mainly similar across groups. Adjusted risk of discontinuation was significantly lower with darolutamide vs enzalutamide (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.61-0.88) and vs apalutamide (HR 0.69, 95% CI 0.54-0.89). Adjusted risk of progression to mCRPC was lower with darolutamide vs enzalutamide (HR 0.63, 95% CI 0.50-0.80) and vs apalutamide (HR 0.72, 95% CI 0.53-0.98). MFS was significantly longer for darolutamide vs enzalutamide (HR 0.65, 95% CI 0.53-0.79) and vs apalutamide (HR 0.72, 95% CI 0.55-0.93). The estimated MFS rates at 24/36 months were 72.3%/60.2% with darolutamide, 59.2%/48.3% with enzalutamide, and 63.9%/47.6% with apalutamide. Darolutamide appeared to be associated with higher PSA response, improved survival, and fewer adverse events vs other ARIs in a real-world setting. Results were consistent in a sensitivity analysis. CONCLUSION: Darolutamide demonstrated lower discontinuation rates, longer time to progression, and longer MFS vs other ARIs, highlighting its potential to enhance real-world patient outcomes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06013475.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Shore ND, George DJ, Khan N, et al. Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study. Prostate Cancer Prostatic Dis. 2026. PMID: 41851476. doi:10.1038/s41391-026-01099-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。